Candidaemia in an Irish intensive care unit setting between 2004 and 2018 reflects increased incidence of Candida glabrata

• Published in: The Journal of hospital infection Vol. 102; no. 3; pp. 347 - 350
• Main Authors: Ryan, P., Motherway, C., Powell, J., Elsaka, A., Sheikh, A.A., Jahangir, A., O'Connell, N.H., Dunne, C.P.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-07-2019
• Subjects: Candida albicans; Candida glabrata; ICU; Increased; Prevalence; Candida albicans; Increased; Candida glabrata; ICU; Prevalence
• ISSN: 0195-6701; 1532-2939
• DOI: 10.1016/j.jhin.2019.01.017

The cumulative incidence of candidaemia in an Irish intensive care unit (ICU) setting between January 2004 and August 2018 was 17/1000 ICU admissions. Candida albicans was responsible for 55% (N=41) of cases. C. glabrata (N=21, 28%) was the next most prevalent species, and has been identified most frequently since 2012. C. glabrata was associated with a higher mortality rate (57%) than C. albicans (29%). All isolates were susceptible to caspofungin (0.05 μg/mL). Notably, 37% of C. glabrata isolates were resistant to fluconazole, with 13% resistant to amphotericin B, highlighting the need for prudent antifungal stewardship to impede development of multi-drug-resistant C. glabrata in the ICU setting.